From Wikipedia, the free encyclopedia
(Redirected from PNU-142,633)
3D model (JSmol)
|Molar mass||422.53 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
PNU-142633 is an experimental drug candidate for the treatment of migraine. It exerts its effect as a selective, high affinity 5-HT1D receptor antagonist. PNU-142633 is well tolerated after oral administration.
- Pregenzer, JF; Alberts, GL; Im, WB; Slightom, JL; Ennis, MD; Hoffman, RL; Ghazal, NB; Tenbrink, RE (1999). "Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands)". British Journal of Pharmacology. 127 (2): 468–72. doi:10.1038/sj.bjp.0702532. PMC . PMID 10385247.
- PNU 142633, Santa Cruz Biotechnology
- Fleishaker, JC; Pearson, LK; Knuth, DW; Gomez-Mancilla, B; Francom, SF; McIntosh, MJ; Freestone, S; Azie, NE (1999). "Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F". International journal of clinical pharmacology and therapeutics. 37 (10): 487–92. PMID 10543315.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|